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Abstract—This paper proposes a constrained control scheme
for the control of the depth of hypnosis during induction phase in
clinical anesthesia. In contrast with existing control schemes for
propofol delivery, the proposed scheme guarantees overdosing
prevention while ensuring good performance. The core idea
is to reformulate overdosing prevention as a constraint, and
then use the recently introduced Explicit Reference Governor
to enforce the constraint satisfaction at all times. The proposed
scheme is evaluated in comparison with a robust PID con-
troller on a simulated surgical procedure for 44 patients whose
Pharmacokinetic-Pharmacodynamic models have been identified
using clinical data. The results demonstrate that the proposed
constrained control scheme can deliver propofol to yield good
induction phase response while preventing overdosing in patients;
whereas other existing schemes might cause overdosing in some
patients. Simulations show that mean rise time, mean settling
time, and mean overshoot of less than 5 [min], 8 [min], and 10%,
respectively, are achieved, which meet typical anesthesiologists’
response specifications.
Index Terms—Automated drug delivery, Anesthesia,
Pharmacokinetic-Pharmacodynamic model, Depth of hypnosis,
Constrained control, Explicit reference governor.
I. INTRODUCTION
A
NESTHESIA means lack of ability to sense, or a state
of being unable to feel anything. More precisely, it is
a temporary reversible state consisting of unconsciousness,
loss of recall, lack of pain perception, and sometimes muscle
relaxation. During surgical procedures, anesthesiologists adjust
the dose of administered anesthetic drug to reach an acceptable
level of anesthesia. From technical viewpoint, their actions can
be interpreted as a manual feedback control. Starting from
this observation in recent years automating drug delivery in
anesthesia has gained more and more attention.
Automated drug delivery in anesthesia involves the contin-
uous administration of an anesthetic drug to achieve loss of
consciousness while maintaining safe vital signs during the
surgery. In general, anesthesia consists of three components
[1]: (i) hypnosis (i.e., loss of consciousness and lack of
awareness), (ii) analgesia (i.e., lack of nociceptive reactivity),
and (iii) neuromuscular blockade (i.e., hemodynamic stability
and immobilization). This paper will deal with the control
of depth of hypnosis through intravenous administration of
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propofol. In other words, the main goal of this paper is to
propose a delivery system that can safely control the depth of
hypnosis by manipulating the infusion rate of propofol.
Propofol hypnosis can be divided into three temporal phases
[2]: (i) induction, (ii) maintenance, and (iii) emergence. The
aim of the induction phase is to bring the patient from total
awareness to a desired depth of hypnosis. Once a stable
depth of hypnosis is achieved, the maintenance phase begins.
Surgery takes place during the maintenance phase. After
completing the surgery, the emergence phase begins, when the
administration of propofol is terminated.
Although controlling the depth of hypnosis during the main-
tenance phase is onerous per se, one of the main challenges in
propofol delivery is to safely administer the drug during the
induction phase despite the patients’ inherent drug response
variability without overdosing them. In this paper, we will
focus on the development of a constrained control scheme to
guarantee overdosing prevention while ensuring an acceptable
hypnosis induction performance.
In recent years a large number of controllers for the control
of the depth of hypnosis have been proposed in the literature.
Indeed, the recent development of devices and techniques to
quantify the depth of hypnosis e.g., the bispectral index [3]
and wavelet-based index [4], has opened up the opportunity
for developing automatic propofol delivery systems. Several
control schemes have been proposed for the control of the
closed-loop control of hypnosis including PID controller [5]–
[8], H∞ controller [9]–[11], multi-model robust control scheme
[12], and event-based controller [13]
The most important confounders in closed-loop hypnosis
control are [9]: (i) the large amount of inter-individual model
variability, and (ii) the persistent and unexpected surgical
stimulation and anesthetic-analgesic interaction throughout the
surgical procedure. The former is an onerous problem during
both induction and maintenance phases, while the latter is an
aspect that is specific to the maintenance phase. It is obvious
that, because of these two confounders, a purely model-
based control scheme cannot effectively control the depth
of hypnosis or may even cause instability. Hence robustness
against those confounders is the main matter of concern in
control schemes presented to control the depth of hypnosis.
Although fundamental for the safety of the patient, to
the best of authors’ knowledge, no scheme to systematically
ensure overdosing prevention during the induction phase has
been proposed yet. Indeed, existing works state that the risk
of overdosing decreases by increasing the robustness of the
system [9], [12], or by adding a set-point prefilter to smooth
the reference signal and reduce possible overshoots [6]. At the
2current stage the absence of schemes guaranteeing overdosing
prevention is one of the aspects that limits the acceptance of
these schemes in the anesthesiology community.
In this paper we will first reformulate the control of depth
of hypnosis during induction phase as a constrained control
problem. Then we will propose a control architecture to con-
trol the induction phase guaranteeing overdosing prevention. In
particular, we will make use of the recently introduced Explicit
Reference Governor (ERG) framework [14]–[18]. The main
idea behind the ERG framework is to determine an invariant
set that would contain the state trajectory if the currently
auxiliary reference were to remain constant. If the distance
between this invariant set and the boundary of the constraints
is strictly positive, it follows from continuity that the derivative
of the auxiliary reference can be nonzero without leading to
constraint violations. If this distance is zero, the satisfaction of
the constraints is ensured by maintaining the current reference
constant. One of the main strengths of the ERG is that it
requires very limited computational capabilities since, unlike
other constrained control schemes (e.g., Model Predictive
Control), it does not make use of online optimization, making
its implementation simple, robust, and easily certifiable.
The rest of the paper is organized as follows. Section
II describes the models used in propofol delivery system.
Section III presents the details of the proposed control scheme.
In Section IV, simulations are carried out using the proposed
scheme and their results are discussed. Finally, Section V
concludes the paper.
II. MODELING OF PROPOFOL DELIVERY SYSTEM
The relationship between dose and pharmacological effect
of administered anesthetic drug (propofol in this paper) is
described by the PharmacoKinetic-PharmacoDynamic (PKPD)
model. The input to this process is the dose of administered
drug, and the output is the clinical hypnotic effect. For the
sake of completeness and for the reader’s convenience, the
overall PKPD model will be hereafter described.
A. PKPD Model
The model which is normally used to explain the response
of a patient to administered aesthetic drug (propofol in this
study) consists of two parts: (i) PK model, and (ii) PD model.
The PK model relates the drug plasma concentration with
the administered dose. Most propofol PK models consider
three compartments [19]: (i) plasma compartment, (ii) shallow
peripheral compartment, and (iii) deep peripheral compart-
ment. Denoting the propofol concentration in the plasma, fast
peripheral, and slow peripheral compartments as C1, C2, and
C3 (all in [mg/l] or [µg/ml]), respectively, and the volume in
the aforementioned compartments as V1, V2, and V3 (all in [l]),
respectively, the state-space representation of the PK model
can be expressed as

C˙1
C˙2
C˙3

=


−(k10+ k12+ k13) k12 k13
k21 −k21 0
k31 0 −k31




C1
C2
C3

+


1
V1
0
0

 I,
(1)
Fig. 1. PKPD model block diagram.
where where I(t) is the infusion rate (in [mg/s]), and
k10 =
Cl1
V1
, k12 =
Cl2
V1
, k21 =
Cl2
V2
, k13 =
CL3
V1
, k31 =
Cl3
V3
, (2)
and Cl1 denotes the elimination clearance, and Cl2 and Cl3 are
inter-compartmental clearances. Note that Vi andCli, i= 1,2,3
are determined using the relations presented in [19].
The PD model relates the plasma concentration with the
pharmacological end-effect. In other words, the PD model
describes the distribution of the propofol in the brain. The
PD model is a first-order plus time-delay system [20], as
PD(s) =
Er(s)
C1(s)
= e−Tds
1
2EC50
kd
s+ kd
, (3)
where Td and kd are the transport delay and rate of propofol
distribution between the plasma concentration and the brain,
and EC50 is the steady-state plasma concentration to obtain
50% of the hypnotic effect. In addition, a nonlinear saturation
function (Hill function) is used to describe the relation between
Er(t) and the clinical hypnotic effect Eo(t), which is
Eo(t) =
(Er(t))
γ
0.5γ +(Er(t))
γ , (4)
where γ is the cooperativity coefficient (see [21] for details on
how to simplify the number of parameters in the Hill curve).
Note that Eo(t) is bounded between 0 and 1; 0 means no
hypnotic effect, 1 is associated with maximum hypnosis.
Combining (1) and (3), and linearizing (4) in the neighbor-
hood of the operating regime, i.e., Er(t) = 0.5 (see Appendix),
the following PKPD model is obtained, which describes the
drug dose-hypnotic effect relationship of propofol:
PKPD(s) = e−TdsKPKPD
(s+ z1)(s+ z2)
(s+ p1)(s+ p2)(s+ p3)(s+ p4)
, (5)
where KPKPD, zi, i = 1,2, and p j, j = 1, · · · ,4 are the gain,
zeros, and poles of the model, respectively.
B. WAVCNS Monitor Model
In this paper, we assume that the clinical hypnotic effect
is measured through the WAVCNS [22]. The dynamics of the
WAVCNS monitor is usually modeled as [6]
H(s) =
Y (s)
Eo(s)
=
1
(8s+ 1)2
, (6)
where Y (s) is the Laplace transform of the WAVCNS index.
3C. Age Groups
In this paper, we will consider the PK and PD model
data identified for 44 patients in [6]. The data consists of
two data sets: (i) the patient characteristics including gender,
age, weight, and height, which are used to calculate the PK
parameters, and (ii) the estimated PD parameters including
Td , kd , EC50, and γ , which are used in the PD model directly
as in (3). As discussed in Section I, the main difficulty in
designing an automatic drug delivery system for anesthesia is
the inherent patient variability. As discussed in [23], patient
age can be used as a criterion to reduce the inter-individual
variability of the PKPD models. Hence, a 10-years bracket
is selected and the 44 patients are subdivided into four age
groups, as Group 1: 18-29 years, Group 2: 30-39 years, Group
3: 40-49 years, and Group 4: 50-60 years.
A nominal model for each age group is identified using the
optimization procedure presented in [6]. The obtained nominal
parameters are presented in TABLE I.
III. CONTROL ARCHITECTURE
This section discusses the development of a constrained
control scheme for the control of depth of hypnosis. Following
the usual Reference Governor philosophy [24], the procedure
consists in first pre-stabilizing the system; then augmenting it
with an add-on unit to enforce constraints satisfaction.
A. Pre-Stabilizing the Propofol delivery system
To stabilize the propofol delivery system, the robust PID
controller designed in [6] will be used. The controller is
implemented with two degrees of freedom as depicted in
Fig. 2, where Gc(s) and G f f (s) are expressed as:
G f f (s) =kp+
ki
s
, (7)
Gc(s) =kp+
ki
s
+ kds. (8)
The numerical values of the parameters for each group are
reported in TABLE II. Note that since it is necessary to protect
the controller from integrator windup, particularly when the
infusion rate is nil, a back-calculation anti-windup scheme is
implemented that resets the integrator dynamically with a time
constant Tt . It should be remarked that the controller parame-
ters are determined based on nominal parameters presented in
TABLE I for each age group. As shown in [2], [25], patient-
individualized schemes can improve the performance of the
system, which is out of the scope of this paper.
For notational compactness, the overall dynamic model of
the pre-stabilized system (green box in Fig. 2) will be denoted
as {
x˙(t) = f (x(t),v(t))
y(t) = h(x(t),v(t))
, (9)
where x ∈ Rn is the state of the pre-stabilized system, y(t) ∈
[0,1] is the output of the system representing the current level
of hypnosis, and v∈ [0,1] is the desired reference of the control
loop, i.e., the desired level of hypnosis. Note that in order to
build (9), the actual PKPD model given in (1)-(4) is used.
TABLE I
OPTIMUM NOMINAL PKPD(s) PARAMETERS.
Parameters Group 1 Group 2 Group 3 Group 4
Td [s] 18.6 16.5 8.3 17.8
KPKPD (10
−4) [1/mgs−1] 1.698 1.928 1.438 1.823
z1 (10
−3) [s−1] 1.477 1.478 1.486 1.478
z2 (10
−5) [s−1] 2.572 2.703 3.627 2.651
p1 (10
−2) [s−1] 3.239 3.843 2.870 3.656
p2 (10
−3) [s−1] 6.961 7.735 7.748 9.100
p3 (10
−4) [s−1] 2.803 2.912 2.843 2.962
p4 (10
−5) [s−1] 2.703 2.787 2.121 2.710
Fig. 2. The two-degrees-of-freedom control scheme presented in [6].
TABLE II
PID PARAMETERS.
Parameters Group 1 Group 2 Group 3 Group 4
kp 2.610 3.947 10.207 4.455
ki 0.026 0.046 0.107 0.058
kd 65.09 85.29 202.38 104.83
Tt [s] 49.819 43.024 43.397 42.416
TABLE III
PASSIVE SET-POINT PREFILTER PARAMETER.
Parameter Group 1 Group 2 Group 3 Group 4
Tsp [s] 156.81 129.90 111.95 124.96
B. Enforcing Constraint Satisfaction
The two-degrees-of-freedom structure presented in the pre-
vious sub-section is sufficiently robust against intra- and inter-
patient variabilities, and guarantees reference tracking in a
reasonable time. However it may cause high overshoot in the
induction phase, which increases the risk of overdosing. Note
that for safety y(t) should be less than 0.6 for all times.
In [6], to cope with this problem, a low-pass set-point
prefilter was introduced
Fsp(s) =
V (s)
R(s)
=
1
Tsps+ 1
, (10)
where Tsp is the time constant of the filter whose values are
reported in TABLE III. The idea is that the set-point pre-
filter (10) generates an auxiliary reference v(t) by smoothing
(reducing the sharpness of) the reference r(t). This decreases
the overshoot, and consequently reduces the overdosing occur-
rences. However, it does not guarantee overdosing prevention.
To guarantee overdosing prevention in all cases one should
increase the time constant Tsp that will lead to a very slow
response. In the next subsection, an analytic approach to
design an active set-point prefilter to guarantee overdosing
prevention at all times without hampering the performance
in an unacceptable way will be presented.
4C. ERG-Based Active Set-Point Prefilter
The ERG framework [17] is an an add-on unit which acts
as an active set-point prefilter. The ERG suitably modifies
the derivative of the auxiliary reference v(t), only when it
is needed, such that constraints are enforced at all times. This
implies that using the ERG scheme as the set-point prefilter
in the structure presented in Fig. 2 can guarantee not only
overdosing prevention but also acceptable performance during
the induction phase. In this subsection we will propose a ERG
scheme specifically designed for the control of the depth of
hypnosis.
Once the propofol delivery system is stabilized by the
proposed two-degrees-of-freedom structure [6], the next step
is to add the constraint-handling capability to make sure that
y(t) ≤ 0.6 for all times. As shown in [18], this can be done
by manipulating the auxiliary reference v(t) according to the
following differential equation
v˙(t) = κ ·∆(t) ·ρ(t), (11)
where κ > 0 is a tuning parameter, and ∆(t) and ρ(t) are
the two fundamental components of the ERG scheme, called
the Dynamic Safety Margin (DSM) and the Navigation Field
(NF), respectively.
The NF represents the direction along a feasible path that
leads from the current auxiliary reference hypnosis level v
to the desired hypnosis level r. In other words, the NF can
be interpreted as the answer to the question “What direction
should the auxiliary reference hypnosis level follow?” [18].
In mathematical terms, ρ : R×R→ R is a NF if, for any
strictly admissible constant desired hypnosis level r ∈ R and
for any admissible initial value v(t0) such that h(xv(t0),v(t0))≤
0.6 where xv(t0) denotes the equilibrium of (9) associated to
v(t0) (i.e., f (xv(t0),v(t0)) = 0), the system v˙(t) = ρ(t) satisfies
h(xv(t),v(t))≤ 0.6, ∀t ≥ t0, (12)
lim
t→∞
v(t) = r. (13)
Since in closed-loop anesthesia the reference is mono-
dimensional, it is sufficient to choose the NF as
ρ(t) =
r− v(t)
max{|r− v(t)|,η}
, (14)
where η > 0 is a smoothing factor.
The DSM represents a distance between the constraint
y(t)≤ 0.6 and the output of the system (9) that would emanate
from the state x(t) for a constant reference hypnosis level v.
In other words, the DSM can be interpreted as the answer to
the question “How safe is it to change the auxiliary reference
hypnosis level v?” [18]. In mathematical terms, ∆ :R×Rn→R
is a DSM if, for a given auxiliary reference hypnosis level v
satisfying h(xv,v)≤ 0.6, the following properties hold true:
• ∆(t) is continuous and bounded for any bounded ‖x‖ and
|v|.
• ∆(t) ≥ 0 implies that if the current auxiliary reference
hypnosis level v is maintained constant, y(t)= h(x(t),v)≤
0.6 for all times.
• ∆(t) > 0 implies that v(t) can be perturbed without
causing constraint violation.
The mentioned properties mean that for given a constant
reference v, ∆(t) is a distance representing how far y(t) is
from 0.6.
As shown in [18], [26], the most intuitive way to compute
the DSM is solving at each time instant the following initial
value problem {
˙ˆx(τ) = f (xˆ(τ),v(t))
xˆ(0) = x(t)
, (15)
and then assigning ∆(t) as
∆(t) = min
τ∈[t,∞)
{0.6− yˆ(τ|t)}, (16)
where yˆ(τ|t) is
yˆ(τ|t) = h(xˆ(τ|t),v(t)). (17)
Clearly, solving (15) at each time instant over an infinite
horizon is inapplicable in practice. To make the approach
applicable, the DSM (18) can be reformulated as
∆(t) = min
τ∈[t,t+T ]
{0.6− yˆ(τ|t)}, (18)
where T is a finite time instant such that xˆ(t+ T |t) ∈ Ω, in
which Ω is an invariant set included in ‖xˆ(τ)− xv(t)‖ ≤ ε ,
with ε > 0 as a design parameter and xv(t) as the equilibrium
point of system (15) (i.e., f (xv(t),v(t)) = 0). For more details
on determining the set Ω and calculating the time instant T ,
please refer to [18], [26].
The aforementioned method to restrict simulation of system
(15) to an finite horizon T ≥ 0 does not compromise the
properties of the DSM [26] and can be used in practice easily.
However, since xˆ(t + T |t) ∈ Ω is the stopping condition for
the trajectory prediction, it is concluded that the prediction
horizon T is not constant. This means that the execution time
of (18) is not known a priori, which can be problematic in
real-time applications.
Observing results of extensive simulations with different
initial conditions and hypnosis reference levels demonstrates
that (9) can be well approximated with a linear system. Clearly,
for linear systems any constant value bigger than the peak
time (the time at which peak value occurs) of the system
can be chosen as the prediction horizon. Also, computing
yˆ(τ|t), τ ∈ [t, t+T ] for a linear system with initial condition
x(t) and input v(t) is easier and less computationally intensive
than (17). Therefore, in the following, first the system (9)
will be approximated by a linear system; then, a procedure
will be presented to modify the resulting DSM in order to
guarantee constraints satisfaction at all times in the presence
of approximation error.
From extensive simulations, it is concluded that the system
(9) can be well approximated with the following linear system{
˙˜x(t) = Ax˜(t)+Bv(t)
y˜(t) =Cx˜(t)+Dv(t)
(19)
5where
A=


A1 0 0 0
0 A2 0 B2C4
B3C1 −B3C2 A3 −B3D2C4
0 0 B4C3 A4

 , (20)
B=
[
BT1 0 (B3D1)
T
0
]T
, (21)
C =
[
0 0 0 C4
]
, (22)
D=0, (23)
with (A1,B1,C1,D1), (A2,B2,C2,D2), (A3,B3,C3,D3), and
(A4,B4,C4,D4) as state-space realization matrices of the feed-
forward controller G f f (s) given in (7), the feedback controller
Gc(s) given in (8), the PKPD model (5), and the sensor (6),
respectively. Note that to compute (A3,B3,C3,D3), the time-
delay operator in (5) is approximated by Pade` approximant.
Therefore, y˜(τ|t) can be computed as
y˜(τ|t) =CeA(τ−t)x(t)+C
∫ τ
t
(
eA(τ−σ)Bv(t)
)
dσ , (24)
for τ ∈ [t, t + T ], where T is bigger than the peak time of
system (19) for all possible initial conditions (see [24] for
details on how to compute this peak time). In this study, it is
assumed that T = 300 [s], which is sufficiently larger than the
peak time of system (19) computed for the 44 patients.
At this point, define the approximation error as eˆ(t), y(t)−
y˜(t). Thus, we can define δ0 as a measure of approximation
accuracy as
δ0 ,max
Gi
sup
t
|eˆ(t)|, (25)
where Gi, i = 1, · · · ,4 is the set of all patients of the i-th
group. Thus, in order to guarantee constraint satisfaction in the
presence of approximation error, we could restrict the DSM
(18) as follows
∆(t) = min
τ∈[t,t+T ]
{0.6− y˜(τ|t)− δ0}. (26)
where δ0 can be interpreted as safety bound to take into
account the mismatch between (15) and (19).
The value of δ0 can be obtained from extensive simulation
studies (Monte Carlo method). Fig. 3 shows response of
closed-loop anesthesia for 1000 simulations for each patient
with successive step-wise reference with random number of
steps, levels, and durations (random initial conditions). From
this figure, obtained values for δ0 are reported in TABLE IV.
Note that although the DSM (26) guarantees constraint
satisfaction at all times, it implies that y˜(t)≤ 0.6−δ0, ∀t ≥ 0.
Since 0.6− δ0 < 0.5 for all age groups, by using the DSM
(26) there would be no guarantee to reach the desired level of
hypnosis, i.e., v(t)9 0.5.
As seen in Fig. 4 (1000 simulation studies for each patient
with random reference hypnosis level) when v(t1) ∈ [0,0.5]
(in this figure t1 = 0 and 10 [min] to have random initial
conditions) and it is kept constant for t ≥ t1, we have the
following lighter time-varying bound
|eˆ(t)| ≤ δ1(t), ∀t ≥ t1, (27)
Fig. 3. Illustration of determining the safety bound δ0; each color for one
patient. Left top: Group 1, right top: Group 2, left bottom: Group 3, right
bottom: Group 4.
TABLE IV
OBTAINED VALUES FOR δ0 .
Parameter Group 1 Group 2 Group 3 Group 4
δ0 0.1350 0.1888 0.1907 0.1354
where
δ1(t) =δ0 (u(t− t1)− u(t− t1− 2))+ δ0e
−
t−t1−2
5 u(t− t1− 2),
(28)
with u(t) as the step function. Using this bound, the DSM (26)
can be replaced by the DSM
∆(t) = min
τ∈[t,t+T ]
{0.6− y˜(τ|t)− δ1(t)}, (29)
where y˜(τ|t) can be computed through (24). Note that the
DSM (29) guarantees reaching the desired level of hypnosis,
i.e., v(t)→ 0.5 (see [18] for details on the theoretical properties
of ERG).
Since the PD model of the patient is not known, to compute
y˜(τ|t) in (24) we have to use the nominal PD model for each
age group. In other words, the matrices A and B in (20)-
(21) should be computed based on the nominal PD parameters
for each age group. Thus, the DSM (29) can only guarantee
constraint satisfaction when applied to the nominal model. In
other words, inter-patient variability should be also taken into
account in calculating DSM.
For this purpose, let define a robustness margin δ2 as follows
δ2 = max
G1,G2,G,G4
sup
t
|e˜(t)|, (30)
where e˜(t) = y˜(t)− y˜ j(t) with y˜ j(t) as the output of the
approximated linear system of the j-th patient with DSM (29).
Thus, in order to guarantee constraint satisfaction even in
the presence of inter-patient variabilities, it is only needed to
further restrict the DSM (29) with an additional static safety
bound as follows
∆(t) = min
τ∈[t,t+T ]
{0.6− y˜(τ|t)− δ1(t)− δ2}. (31)
Extensive simulations (1000 simulations for each patient
with random reference hypnosis level) have been carried out
to determine the value of the safety parameter δ2. Simulation
6Fig. 4. Illustration of determining the safety bound δ1; each color for one
patient. Left top: Group 1, right top: Group 2, left bottom: Group 3, right
bottom: Group 4.
Fig. 5. Illustration of determining safety bound δ2; each color for one group.
results for all 44 patients are shown in Fig. 5. As seen in this
figure, δ2 = 0.08 is sufficient to cover the error caused due to
inter-patient variability in all age groups.
It should be remarked that the main advantage of the DSM
(31) is its simplicity and the low computational associated to
its computation, which makes the DSM (31) computable for
real-time propofol delivery purposes even on cheap hardware.
In summary, the active set-point prefilter based on ERG
framework is implemented as (11) where ρ(t) and ∆(t) are
computed through (14) and (31), respectively. Note that since
the proposed method is designed based on the parameters of 44
patients, in order to make sure that the method is robust against
larger uncertainties that might not be seen in simulation studies
or may exist in different set of patients, the safety bounds are
assumed 5% bigger than the calculated values.
IV. RESULTS AND DISCUSSION
Using the proposed ERG solution with κ = 105, η = 0.01,
all 44 virtual surgeries (i.e., 44 patients) are simulated in
the MATLAB/Simulink environment using the actual PKPD
model (1)-(4). For the purpose of comparison, we have also
simulated the two-degrees-of-freedom structure without pre-
filter and with the passive prefilter presented in [6].
Constraint on the amplitude of the propofol infusion rate
I(t), is in part due to hard physical constraints on the system.
The infusion rate can obviously not be negative, and maximum
infusion rate can be enforced to minimize hemodynamic
changes. Hence, by assuming that propofol 10 [mg/ml] is be-
ing used as the hypnotic drug, the infusion rate is constrained
between 0 and 600 [ml/h] [27].
Fig. 6. Closed-loop response of all 44 patients.
TABLE V
COMPARISON OF THE NUMBER OF OVERDOSED PATIENTS.
Without With Passive With ERG
Prefilter Prefilter
Overdosed Patients 44 5 0
The simulations are run on an Intel(R) Core(TM)i7-7500U
CPU 2.70 GHz with 16.00 GB of RAM. The mean compu-
tation time for computing x¯(τ) for τ ∈ [t,T ] through (24) is
4.768 [ms], which according to the fact that the response time
of the propofol delivery system is in the order of minutes, it
is largely acceptable for real-time implementation.
The resulting closed-loop time responses are shown in
Fig. 6-8. Note that for the sake of simplicity and convenience,
the depth of hypnosis DOH(t) is defined as follows:
DOH(t), 100 · (1− y(t)), (32)
where DOH(t) = 100 represents a wakeful state and DOH(t)=
0 represents the maximum level of hypnosis.
As seen in Fig. 6-7, the ERG-based active set-point prefilter
can effectively prevent overdosing in all patients while tracking
the reference signal. When the passive prefilter is used, five
patients in total are in danger of overdosing. Note that without
prefiltering the reference signal, all the patients are in the
danger of overdosing (see TABLE V).
Time-profile of the auxiliary reference signal v(t) when
using the proposed technique is presented in Fig. 8. As
seen in Fig. 8, the ERG acts as an active set-point prefilter
that manipulates the auxiliary reference v(t) only when the
manipulation does not lead to constraint violation. In simple
terms, by using the ERG, instead of applying the desired level
of hypnosis instantly, we apply the auxiliary reference v(t)
that automatically converges to the desired level of hypnosis
so that overdosing prevention is guaranteed at all times.
7Fig. 7. Infusion rate of all 44 patients.
Fig. 8. Auxiliary reference signal v(t) of all 44 patients.
TABLE VI
PERFORMANCE COMPARISON.
Age Group Without With Passive With ERG
Prefilter Prefilter
Rise Time [min]
mean±SD 1.71±0.21 5.09±0.36 4.62±1.24
[min,max] [0.99,2.58] [2.22,9.80] [1.47,11.57]
Settling Time [min]
mean±SD 8.53±1.26 6.15±0.83 8.10±2.08
[min,max] [3.92,35.01] [3.26,27.68] [3.83,22.42]
Overshoot [%]
mean±SD 44.60±3.59 6.27±3.23 9.25±0.89
[min,max] [24.69,85.42] [0.50,57.30] [2.07,19.99]
TABLE VI shows the performance of the two-degrees-of-
freedom structure without prefilter, with the passive prefilter
proposed in [6], and with ERG-based active prefilter, com-
paring rise time, settling time, and overshoot. SD stands for
standard deviation. As seen in this table, settling time and
overshoot is increased by using the ERG-based set-point pre-
filter. However, these increments do not lead to overdosing the
patients. More precisely, the active set-point prefilter increases
the overshoot and settling time in a wise manner to make sure
that the patients will never be in the danger of overdosing.
The amount of used propofol used in first eight minutes to
bring the patients to desired level of hypnosis is presented in
TABLE VII
COMPARISON OF USED PROPOFOL.
Age Group Without With Passive With ERG
Prefilter Prefilter
Used Drug [ml]
mean±SD 30.85±4.75 24.23±3.86 25.76±4.11
[min,max] [14.99,46.85] [12.42,35.72] [14.04,38.56]
Fig. 9. Closed-loop response of 44 patients with measurement noise.
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Fig. 10. Closed-loop response of Patient#1, #6, and #7 given in [28].
TABLE VII. As seen in this table, the two-degrees-of-freedom
structure with ERG-based active set-point prefilter tends to use
almost the same amount of propofol of the passive one.
In order to study the performance of the proposed scheme in
the presence of measurement noise, a white noise signal with
0 mean value and 0.1 (20% of the desired reference) as its
variance is added after the Hill saturation element. Closed-loop
response is shown in Fig. 9. Since to limit the measurement
noise a post-processing trending second-order IIR filter was
added to the WAVCNS monitor [22], measurement noise does
not affect the performance of the proposed ERG scheme too
much. As seen in Fig. 9, although the constraint is violated
for some patients, the overall performance is acceptable in the
presence of such high measurement noise.
A new set of data using the NeuroSENSE monitor is
identified in [28], which consists of data for 1 patient between
30 and 40 years, 2 patients between 50 and 60 years, and 6
patients above 60 years. Here, we use the proposed method to
anesthetize the patients that are in the age range from 18 to
60 years, i.e., Patient#1, #6, and #7. As shown in Fig. 10, the
proposed ERG scheme effectively prevents overdosing, while
tracking the desired level of hypnosis.
V. CONCLUSION
This paper proposed a control scheme structure based on
Explicit Reference Governor framework to control the depth of
hypnosis during induction phase. Using the proposed scheme,
it was show that it is possible to develop an automatic propofol
delivery system that can be proven to guarantee overdosing
prevention and to provide acceptable performance. The pro-
posed scheme was validated in comparison with a robust PID
controller and by simulating 44 patients. The results showed
8the scheme’s effectiveness in controlling the depth of hypno-
sis and overdosing prevention. More precisely, the proposed
scheme exhibited induction phase response with mean rise and
settling times of 5 and 8 minutes, as well as mean overshoot of
less than 10%, which meet anesthesiologist’s response specifi-
cations. Future work includes extending the current work to the
development of multi-constraint propofol delivery system in
which overdosing and blood pressure changes are addressed as
safety constraints, evaluating the proposed constrained control
scheme using real clinical trials, and investigating constrained
control scheme parameterized in patients’ weight. Note that
although with a weight-parameterized scheme it is expected
to achieve better performance, it requires much more clinical
data than those actually available in the literature.
APPENDIX
The Hill function acts as a time-varying gain. For transient
time, the linear gain can be approximated as a straight line
passing through the origin and Er = 0.5, which gives a
constant slope of unity, i.e., GH = 1 [7]. Around operating
regime (i.e., Er = 0.5), the linearized gain depends only on
the hill steepness coefficient and is equal to GH = γ/2. We
define the Hill linearization error as eH(t) , ynH(t)− ylH(n),
where ynH(t) and ylH(t) are the output of the system with
nonlinear and linearized Hill function, respectively. Fig. 11
shows linearization errors obtained with GH = 1 (blue line)
and the one obtained with GH = γ/2 (black line) for all 44
patients. As seen in this figure, not only linearizing the Hill
function around Er = 0.5 leads to less error compared with the
case with GH = 1, but also the error with GH = γ/2 converges
to zero. The advantage of latter property is revealed in (27),
where it admits to define a vanishing safety parameter δ1 to
ascertain desired reference tracking.
Fig. 11. Error caused by the Hill linearization as a gain of 1 and of γ/2.
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